Compare Prudential Financial Inc (PRU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs BIO-TECHNE Corp — how do they compare? Prudential Financial Inc trades at $118.18 (market cap $40.97B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Prudential Financial Inc is far larger — about 3.7× BIO-TECHNE Corp's market cap, and Prudential Financial Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| PRU | TECH | |
|---|---|---|
Market Cap | $40.97B | $11.16B |
Sector | Financials | Health |
52-Week High | $119.07 | $72.12 |
52-Week Low | $92.00 | $43.31 |
Enterprise Value | $68.03B | $11.24B |
Dividend Yield | 4.75% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $118.59, down 0.4% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 12.15, net income margin of 5.5%, and consistent earnings beats in recent quarters. Recent business developments include expanding retirement offerings and international growth initiatives, supported by strong cash flow generation of $6.27B from operations in 2025.
PRU presents a compelling value opportunity with attractive valuation metrics and steady profitability, though analyst sentiment remains cautious with 68% hold ratings. Key risks include significant investing outflows and debt levels, while catalysts include upcoming Q2 earnings and continued retirement market expansion. The stock trades above consensus price targets, suggesting limited near-term upside potential despite fundamental strength.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
